SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Appointment Of Directors
The Board of Directors at their meeting held on May 26, 2023, inter alia, have approved the following: 1. Appointment of Mr. Rolf Hoffmann as an Independent Director 2. Appointment of Mr. Aalok Shanghvi as a Whole-time Director SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update
In connection with our earnings call held on May 26, 2023, we wish to update that Global Ilumya sales for FY23 were US$ 477 million, up by about 51% as compared to FY22. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Q4FY23 Investor Call Audio Recording
Q4FY23 Investor call audio recording SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the disclosure of related party transactions for the half year ended March 31, 2023 is enclosed herewith. Q4FY23 Quarterly & FY23 Annual Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries announced Q4FY23 & FY23 results: Q4FY23: Gross sales at Rs 1,07,256 million, growth of 14.3% vs Q4 last year India formulation sales at Rs 33,641 million, up 8.7% vs Q4 last year US formulation sales at US$ 430 million, up 10.5% vs Q4 last year Global specialty sales at US$ 244 million, including US$ 6.8 million milestone received in Q4. Ex-milestone, up 28% vs Q4 last year Global specialty sales, ex-milestone, accounted for 18.2% of Q4FY23 overall sales Emerging Markets formulation sales at US$ 221 million, up 7.5% vs Q4 last year Rest of World formulation sales at US$ 191 million, up 7.4% vs Q4 last year R&D; investments at Rs 6,657 million compared to Rs 5,433 million for Q4 last year EBITDA at Rs 28,021 million, up 19.7% vs Q4 last year. EBITDA margin for Q4 at 25.6% vs 24.8% for Q4 last year. Reported net profit for Q4FY23 was Rs 19,845 million compared to net loss Rs 22,773 mn for Q4 last year. Excluding the exceptional items, adjusted net profit for Q4FY23 was Rs 21,559 million, up 36.3% over Q4 last year. FY23: Gross sales at Rs 4,32,789 million, growth of 12.6% over same period last year India formulation sales at Rs 1,36,031 million, up 6.6% over same period last year US formulation sales at US$ 1,684 million, up 10.3% over same period last year Global specialty sales at US$ 871 million, up 29% over same period last year Emerging Markets formulation sales at US$ 983 million, up 8.6% over same period last year Rest of World formulation sales at US$ 752 million, up 2.7% over same period last year R&D; investments at Rs 23,676 million compared to Rs 22,194 million for FY22 EBITDA at Rs 1,16,468 million up 12% over same period last year. EBITDA margin for FY23 at 26.5% vs 26.9% for same period last year. Reported net profit for FY23 was Rs 84,736 million compared to Rs 32,727 million for FY22 Excluding the exceptional items, adjusted net profit for FY23 was Rs 86,450 million, up 12.8% over same period last year Dilip Shanghvi, Managing Director of the Company said, “I am pleased with well-rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well. Our Specialty business remains on growth path and we are committed to continue scaling it up. Acquisition of Concert helps further strengthen our portfolio in dermatology. I believe deuruxolitinib can become a leading product to address highly unmet need in alopecia areata patients.” Result PDF SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Financial results for the fourth quarter ending March 31th, 2023. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
With reference to the intimation of Board meeting submitted on May 11, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. May 26, 2023 which commenced at 10:40 a.m. and ended at 02:35 p.m., wherein the Board has, inter-alia, Recommended Final Dividend for financial year 2022-23 Final dividend of Rs. 4.00/- (Rupees Four only) per equity share of Re. l/- (Rupee One only) each of the Company is recommended subject to approval of the shareholders at the ensuing 31st Annual General Meeting and which shall be paid within the timelines as required under the Companies Act, 2013. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Results For The Quarter And Year Ended March 31, 2023
With reference to the intimation of Board meeting submitted on May 11, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. May 26, 2023 which commenced at 10:40 a.m. and ended at 02:35 p.m., wherein the Board has, inter-alia, 1. Approved Financial Results for the fourth quarter and year ended March 31, 2023 2. Recommended Final Dividend for financial year 2022-23
Sun Pharma Preview: Strong specialty biz, robust domestic sales to boost company's health in Q4
The company's specialty business is likely to post double-digit on-year growth in the quarter, despite some sequential moderation, according to brokerages.